Transmedics Group Inc
NASDAQ:TMDX

Watchlist Manager
Transmedics Group Inc Logo
Transmedics Group Inc
NASDAQ:TMDX
Watchlist
Price: 93.5 USD -0.72% Market Closed
Market Cap: 3.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+18%
Revenue
Forecast
+5%
Operating Income
Forecast
+10%
Net Income
Forecast
+14%

Wall Street
Price Targets

TMDX Price Targets Summary
Transmedics Group Inc

Wall Street analysts forecast TMDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TMDX is 117.94 USD with a low forecast of 80.8 USD and a high forecast of 187.95 USD.

TMDX Lowest Forecast
Wall Street Target
80.8 USD
14% Downside
TMDX Average Forecast
Wall Street Target
117.94 USD
26% Upside
TMDX Highest Forecast
Wall Street Target
187.95 USD
101% Upside
Lowest
Price Target
80.8 USD
14% Downside
Average
Price Target
117.94 USD
26% Upside
Highest
Price Target
187.95 USD
101% Upside
Transmedics Group Inc Competitors:
Price Targets
AXGN
AxoGen Inc
62% Upside
E
ELMD
Electromed Inc
64% Upside
NPCE
Neuropace Inc
54% Upside
2190
Zylox-Tonbridge Medical Technology Co Ltd
3% Upside
AXGN
AxoGen Inc
62% Upside
E
ELMD
Electromed Inc
64% Upside
NPCE
Neuropace Inc
54% Upside
2190
Zylox-Tonbridge Medical Technology Co Ltd
3% Upside
W
336570
Won Tech Co Ltd
16% Downside
BFLY
Butterfly Network Inc
109% Upside
PODD
Insulet Corp
24% Upside
COH
Cochlear Ltd
12% Upside

Revenue
Forecast

Revenue Estimate
Transmedics Group Inc

For the last 7 years the compound annual growth rate for Transmedics Group Inc's revenue is 78%. The projected CAGR for the next 3 years is 21%.

78%
Past Growth
21%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Transmedics Group Inc

The compound annual growth rate of Transmedics Group Inc's operating income for the next 3 years is 55%.

N/A
Past Growth
55%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Transmedics Group Inc

The compound annual growth rate of Transmedics Group Inc's net income for the next 3 years is 42%.

N/A
Past Growth
42%
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

See Also

Summary
TMDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
TMDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TMDX stock valuation using valuation multiples.
Wall Street Estimates
TMDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TMDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TMDX's stock price target?
Price Target
117.94 USD

According to Wall Street analysts, the average 1-year price target for TMDX is 117.94 USD with a low forecast of 80.8 USD and a high forecast of 187.95 USD.

What is Transmedics Group Inc's Revenue forecast?
Projected CAGR
21%

For the last 7 years the compound annual growth rate for Transmedics Group Inc's revenue is 78%. The projected CAGR for the next 3 years is 21%.

What is Transmedics Group Inc's Operating Income forecast?
Projected CAGR
55%

The compound annual growth rate of Transmedics Group Inc's operating income for the next 3 years is 55%.

What is Transmedics Group Inc's Net Income forecast?
Projected CAGR
42%

The compound annual growth rate of Transmedics Group Inc's net income for the next 3 years is 42%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.